Which specific osteoclast-activating factor is heavily upregulated and secreted by malignant plasma cells in Multiple Myeloma, aggressively driving the classic ‘punched-out’ lytic bone lesions while simultaneously uncoupling normal bone remodeling?

Explanation:
The correct option is a. The pathophysiology of myeloma bone disease is characterized by a severe, localized uncoupling of the normal bone remodeling process. Malignant plasma cells directly upregulate the expression of RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand) while simultaneously suppressing the production of its decoy receptor, Osteoprotegerin (OPG), in the bone marrow microenvironment. The immense excess of free RANKL powerfully stimulates osteoclastogenesis and hyperactivates mature osteoclasts, leading to aggressive bone resorption. Furthermore, myeloma cells secrete Dickkopf-1 (DKK1), which blocks the Wnt signaling pathway, severely crippling osteoblast function. This dual action—massive osteoclastic destruction without any compensatory osteoblastic bone formation—results in the classic purely lytic, 'punched-out' lesions without sclerotic margins, which is why standard technetium-99m bone scans (which detect osteoblastic activity) are notoriously false-negative in multiple myeloma. Reference: Roodman GD. Pathogenesis of myeloma bone disease. Leukemia.